Clinical trials: Portal Vein Embolization
Hepatocellular Carcinoma
Efficacy of Sequential TACE and PVE on the Resectability of Hepatitis B Related HCC
A primary hepatocellular carcinoma (HCC) is generally regarded as unresectable if the future liver remnant (FLR)≤40％ of total liver volume in patient with underlying liver disease, such as hepatitis B.
- Trial name
- TACEPVE (NCT00834158)
- Testing
- TACE, PVE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Biliary Tract Cancer, Portal Vein Embolization
Effect of PVE on Surgical Outcomes and Long-term Survival in Perihilar Cholangiocarcinoma
Portal vein embolization is often recommended to reduce the risk of postoperative liver failure and mortality. In this retrospective cohort study, researchers investigated the effect of portal vein embolization in patients with…
- Trial name
- NCT06222619
- Testing
- Potal vein embilization
- Where
- South Korea
- Volunteers
- 136 people
- Sponsor
- Seoul National University Hospital
Colorectal Cancer, Liver Metastases
ALPPS Versus PVE/PL
Study Title Comparison of two different models of liver growth stimulation in advanced colorectal liver metastatic disease, (LIGRO Trial) enabling liver resection Methodology Scandinavian Multiple Center Randomized Registry Based…
- Trial name
- LIGRO (NCT02215577)
- Testing
- In-situ split, Portal embolization or ligation
- Where
- 7 sites in Denmark, Norway and 1 more
- Volunteers
- 100 people
- Sponsor
- Regionalt Cancercentrum Väst
Liver Cancer, Liver Metastases
Impact of PVE on Patient's Long-term Survival, Complications and Cancer Recurrence.
For patients with colorectal liver metastasis (CLM), the prospect of long-term survival relies on liver resection. Wistfully, more than 75 % of patients with CLM are initially unresectable, due to an insufficient future liver…
- Trial name
- NCT03168230
- Testing
- Portal vein embolization (PVE)
- Volunteers
- 128 people
- Sponsor
- Université de Sherbrooke
Cavernous Transformation of Portal Vein, Gastroesophageal Varices Bleeding
Efficacy and Safety of Variceal Embolization Combined With Partial Splenic Artery Embolization for Variceal Bleeding in Cavernous Transformation of Portal Vein.
The management of variceal bleeding in patients with cavernous transformation of portal vein (CTPV) generally adheres to the principles applied to cirrhotic portal hypertension, including pharmacological therapy, endoscopic…
- Trial name
- NCT07310316
- Testing
- Variceal Embolization Combined With Partial Splenic Artery Embolization
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Air Force Military Medical University, China
Liver Resection, Cancer
Regeneration of Liver: Portal Vein Embolization Versus Radiofrequency Assisted Ligation for Liver Hypertrophy (REBIRTH)
The aim of this study is to compare two different techniques (portal vein embolization and radiofrequency assisted liver partition with portal vein ligation) for increasing liver volume prior to major liver resection.
- Trial name
- REBIRTH (NCT02216773)
- Testing
- Radiofrequency assisted liver partition with portal vein ligation (RALPP), Portal vein embolization (PVE)
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- Imperial College London
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver
HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization
This phase IIb trial tests the effect of HRX215 in treating patients with colorectal cancer that has spread from where it first started to the liver (liver metastasis) after undergoing a portal vein embolization (PVE).
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT07612007
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Liver Venous Deprivation
A Clinical Study of Portal Vein Embolization and Liver Venous Deprivation
The main obstacle to achieving R0 resection in future liver remnant（FLR） deficient liver cancer is the inability to retain sufficient FLR to avoid postoperative liver failure.
- Trial name
- NCT05457374
- Testing
- PVE, LVD
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Anhui Provincial Hospital
Arteriovenous Malformation, Gastrointestinal Bleed
Case-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils
The purpose of the Case-Specific Health Care Professional (HCP) Clinical Survey for Concerto Versa™ Detachable Coils, also known as the Concerto Versa HCP Clinical Assessment, is to collect early clinical data from HCPs to assess…
- Conditions
- Arteriovenous Malformation, Gastrointestinal Bleed, Gastric Varices, Hemorrhoid
- Trial name
- NCT07639853
- Testing
- Concerto Versa™ Detachable Coils
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Medtronic Endovascular
Hepatocellular Carcinoma (HCC)
Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis
Portal vein tumor invasion (PVT) is a common complication in HCC. the studyb Aimed to assess the outcomes after TACE in patients with branch PVT regarding Child classification, radiological response and 1 year survival.
- Trial name
- NCT03007212
- Testing
- transarterial chemoembolization versus the standard treatment with sorafinib
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Ascites, Liver Cirrhosis
Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis
The purpose of this study is to learn whether a procedure called Proximal Splenic Artery Embolization (PSAE) can lower the need for repeat fluid drainage in adults with cirrhosis and a buildup of fluid in the abdomen (ascites)…
- Conditions
- Ascites, Liver Cirrhosis, Hypertension, Portal
- Trial name
- NCT07755059
- Testing
- Proximal Splenic Artery Embolization
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Procedure-Related Complication, Degree of Liver Regeneration
Ipsilateral Hepatic Vein Embolization After Portal Vein Embolization
Portal vein embolization (PVE) induces shrinkage of the embolized lobe and compensatory enlargement of the non-embolized lobe, but it does not always induce sufficient liver regeneration.
- Trial name
- NCT00698880
- Testing
- Right hepatic vein embolization
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- Asan Medical Center
Hepatocellular Carcinoma
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
Although resection provided survival benefit for selected HCC patients with PVTT, the recurrence rate is still high for those patients.
- Trial name
- NCT06031285
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-sen University
Liver Regeneration, Reversible Portal Vein Embolization
Reversible Portal Vein Embolization Before Major Hepatectomy
The aim of this study is to prospectively evaluate the tolerance and efficiency of a new technique of preoperative selective portal vein embolization (PVE) in patients requiring major hepatic resection.
- Trial name
- EMBORES (NCT02945059)
- Testing
- Selective reversible portal vein embolization
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Portal Vein Embolization, Liver, Hypertrophy
Comparison of N-butyl-cyanoacrylate and Micro Parti-cles Effect in Inducing Liver Hypertrophy After PVE
The aim of this study is to compare hypertrophy of the FLR after PVE with microparticles to hypertrophy after PVE with cyanoacrylate in a material large enough to answer the study question.
- Trial name
- NCT05660759
- Testing
- Portal vein embolization
- Where
- Sweden
- Volunteers
- 265 people
- Sponsor
- Linkoeping University
Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis
Transarterial Chemoembolization (TACE) With Radiation Therapy (RT) in Advanced Hepatocellular Carcinoma (HCC)
The presence of portal vein tumor thrombosis (PVTT) in patients with hepatocellular carcinoma (HCC) is one of the most significant prognostic factors for poor prognosis, without treatment, their survival is less than 3 months.
- Trial name
- NCT02290977
- Testing
- Scheduled interval TACE - RT
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Hepatic Neoplasm
Scandinavian Cohort Study for Optimal Use of Portal Vein Embolization
Several aspects on the use of portal vein embolization (PVE) are poorly studied and todays recommendations are based on low-grade evidence.
- Trial name
- NCT04182386
- Testing
- Portal vein embolization
- Where
- Sweden
- Volunteers
- 300 people
- Sponsor
- Karolinska University Hospital
Hepatocellular Carcinoma
Outcome of Hepatocellular Carcinoma Patients With Portal Vein Thrombosis After Trans-Arterial Chemo Embolization
Hepatocellular carcinoma (HCC) is the fifth most common neoplasm worldwide and the third most frequent cause of death from cancer in the world.
- Trial name
- NCT05491889
- Testing
- trans arterial chemoembolization
- Volunteers
- 30 people
- Sponsor
- Assiut University
Major Hepatectomy
Segment IV Hypertrophy After Liver Venous Deprivation
before major hepatectomy, in case of insufisant future liver remanent volume or function, portal embolization is a routinely used method to enable growth of the future liver remnant.
- Trial name
- NCT04370132
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Montpellier
Hepatocellular Carcinoma
Combine TACE and RFA Versus TACE Alone for HCC With PVTT
The purpose of this study is to determine whether combined radiofrequency ablation and transcatheter chemoembolization (TACE) result in better survival outcomes than TACE alone in patients with HCC and portal vein tumor thrombus.
- Trial name
- CORTT (NCT02301091)
- Testing
- TACE, RFA, pirarubicin,mitomycin and lobaplatin
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Ming Zhao